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BY-NC-ND license (http://creativecomBackground/Purpose: Previously, we successfully identified oral cancer stem cells (OCSC) dis-
playing enhanced stemness and tumorigenic potentials. In the study, we investigated the
chemotherapeutic effect of the flavonoid luteolin, commonly found in fruits and vegetables,
on targeting OCSC.
Methods: Oralspheres was applied to isolate OCSC. aldehyde dehydrogenase 1 activity and
CD44 positivity of OCSC with luteolin treatment were assessed by flow cytometry analysis.
Radio-sensitivity of OCSC treated with luteolin was examined. Invasion and colony-forminghave no conflicts of interest relevant to this article.
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Luteolin enhances radio-sensitivity in OSCC 1033assays were performed to assess oncogenicity in OCSC. The expression of interleukin-6 (IL-6)/
signal transducer and activator of transcription 3 (STAT3) was examined by enzyme-linked
immunosorbent assay and western blot analysis.
Results: We showed that luteolin effectively inhibited the proliferation rate, self-renewal,
aldehyde dehydrogenase 1 activity, and CD44 positivity of OCSC but did not cause significant
cytotoxicity of normal epithelial cells. Moreover, luteolin restored radio-sensitivity in OCSC.
Combined treatment with luteolin and radiation displayed synergistic effect on invasiveness
and clonogenicity of OCSC. Mechanistically, treatment of luteolin resulted in inactivation of
IL-6/STAT3 signaling.
Conclusion: These results suggest that combined treatment of luteolin and radiation therapy
can attenuate tumorigenicity of OCSC through IL-6/STAT3 signaling inactivation.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The cancer stem cells theory postulates that a subpopula-
tion of cells termed cancer stem cells (CSC) or tumor-
initiating cells, drive tumor initiation, radio-resistance,
progression, and high rate of relapse and metastasis; thus
development of a novel approach targeting CSC is
imperative.1e5 Our group has previously identified a func-
tional subset of oral CSC (OCSC) in oral squamous cell car-
cinomas (OSCC) marked by oralspheres,6 CD133,7 aldehyde
dehydrogenase (ALDH),3 membrane 78 kDa glucose-
regulated protein (GRP78),8 or side population.9 We also
demonstrated that these OCSC display enhanced tumori-
genic potential in vitro and in vivo. Screening novel com-
pounds for drug candidates that targets the CSC of OSCC
specifically will be instrumental for future advanced OSCC
therapy.
Luteolin (30,40,50,70-tetrahydroxyflavone), belonging
to the flavone subclass, is found in plants such as chamo-
mile tea, celery, perilla leaf, and green peppers.10
Through a variety of experimental cancer models,
luteolin has been found to possess pleiotropic antineo-
plastic activity including stimulation of cancer cell
apoptosis, cell cycle arrest, repression of cancer cell
proliferation, suppressing angiogenesis, and metastasis
capacity.11e13 Evidence suggests that luteolin inhibits
proliferation and induces apoptosis of cancer cells via
protein kinase B/Akt, p38, c-Jun N-terminal kinases, or
nuclear factor-kB signaling.14e17 Luteolin can reverse
multidrug resistance in a variety of cancer cells.16
Luteolin chemosensitizes ovarian cancer cells to pacli-
taxel through repression of epithelialemesenchymal
transition markers and traits.18 Luteolin inhibits the
metastasis of cancer cells in vitro and in vivo through
inhibiting epithelialemesenchymal transition, integrin b1,
or focal adhesion kinase.19 However, the efficacy of
luteolin on the specific subset of OCSC has not been
addressed. In this study, we investigated whether luteolin
possesses anti-CSC effect and whether interleukin-6 (IL-6)/
signal transducer and activator of transcription 3 (STAT3)
signaling is involved in luteolin-targeted CSCs in OSCC
cells.Materials and methods
Cell culture and reagents
Normal human gingival epithelioid S-G cells and OSCC cells
lines (SAS and GNM) were cultivated as previously
described.20 Luteolin was purchased from SigmaeAldrich
(St Louis, MO, USA).
Cell proliferation determination by MTT assay
Cells were plated in wells of 96-well-plate as 1 104 cells/
well in 0.1% dimethyl sulfoxide (DMSO) or different con-
centrations of luteolin-containing medium and cultured at
37C for 24 hours. Cell proliferation/survival was deter-
mined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] assay. The 570 nm absorbance of
the DMSO-treated group was set as 100% and data are
presented as percentage of DMSO control.21
Oralsphere-forming assay
OSCC cells will be dissociated and cultured as oralspheres in
modified Dulbecco’s modified Eagle medium/F-12 supple-
mented with N-2 (R&D, Minneapolis, MN, USA), 10 ng/mL
epidermal growth factor (EGF; Invitrogen, Carlsbad, CA,
USA), 10 ng/mL basic fibroblast growth factor (bFGF; Invi-
trogen), and penicillin/streptomycin at 103 live cells/low-
attachment six-well plate (Corning Inc., Corning, NY,
USA), with the medium changed every other day until
oralsphere formation was observed in about 2 weeks. For
serial passage of oralsphere cells, single cells were ob-
tained from Accutase (SigmaeAldrich)-treated spheroids at
a cell density of passage of 1000 cells/mL in the serum-free
medium described above.2
Flow cytometry analysis for cancer stemness
marker
The ALDEFLUOR kit (Stem Cell Technologies, Durham, NC,
USA) was used to examine the ALDH enzymatic activity
1034 D.-G. Tu et al.according to the protocol described.21 For CD44 analysis,
cells were stained with anti-CD44 antibody conjugated to
phycoerythrin (Miltenyi Biotech., Auburn, CA, USA), with
labeling according to the manufacturer’s instructions. Red
(>650 nm) fluorescence emission from 10,000 cells illumi-
nated with blue (488 nm) excitation light was measured
with a FACSCalibur (Becton Dickinson, Mountain View, CA,
USA) using CellQuest software.21
Invasion and soft agar colony forming assay
Cell invasion and soft agar colony forming assays were
performed as described previously.5
Western blot assay
The analysis was performed to detect the expression of p-
Stat3 and glyceraldehyde 3-phosphate dehydrogenase as
described previously.3
Statistical analysis
SPSS software (version 13.0; SPSS, Inc., Chicago, IL, USA)
was used for statistical analysis. The presented results areFigure 1 Diminished proliferation and self-renewal properties o
treatment shows that concentration-dependent inhibition of cell vi
assessed and presented as percent survival relative to untreated c
cells was examined. The bar graph shows quantification of seconda
and representative results are shown. Results are means standarrepresentative of three independent experiments with
similar results. Statistical differences were evaluated with
the Student t test, and were considered significant at
p< 0.05.
Results
Luteolin attenuated self-renewal ability in oral
cancer stem cells
Initially, we examined the cytotoxic effect of luteolin to
sphere-forming OCSC isolated from SAS and GNM. Luteolin
treatment exerted an antiproliferation effect on OCSC in a
dose-dependent manner, whereas the inhibition on normal
oral epithelial cells (SG) proliferation was limited (Fig. 1A).
As shown in Fig. 1B, luteolin treatment dose-dependently
inhibited secondary sphere-forming ability, an index of
self-renewal in CSCs, in OCSC.
Luteolin inhibited ALDH1 activity and CD44
expression in OCSC
Accumulated evidence indicates that the maintenance
of cancer stemness in OCSC are via high CD44 expressionf oral cancer stem cells with luteolin treatment. (A) Luteolin
ability in oral cancer stem cells by MTT assay. Cell survival was
ells. (B) Secondary sphere formation ability of luteolin-treated
ry sphere number. The experiments were repeated three times
d deviation. * p< 0.05; ** p< 0.001.
Luteolin enhances radio-sensitivity in OSCC 1035and ALDH1 activity.22 Elevated ALDH1 activity and
CD44 expression also mediate tumorigenicity and radio-
chemoresistance. To examine further the anti-CSC
effect of luteolin on eliminating OCSC, we performed
ALDH activity and flow cytometry assays to investigateFigure 2 Reduced CD44 expression in luteolin-treated oral cance
dependently treated with or without luteolin was assessed by flow
positive cells. The experiments were repeated three times and re
deviation. * p< 0.05 versus control.
Figure 3 Luteolin dose-dependently represses aldehyde dehydro
stem cells were dose-dependently treated with luteolin for 24 hou
ALDEFLUOR flow cytometry-based assay. N,N-diethylaminobenzald
negative control. The bar graph shows quantification of ALDH1-po
representative results are shown. Results are means standard deluteolin’s inhibition of CD44 positivity and ALDH activity
of OCSC. By flow cytometry analysis, luteolin treat-
ment significantly reduced CD44 population (Fig. 2) and
ALDH1 activity (Fig. 3) in OCSC in a dose-dependent
manner.r stem cells. The CD44 positivity of oral cancer stem cells dose-
cytometry analysis. The bar graph shows quantitation of CD44-
presentative results are shown. Results are means standard
genase (ALDH) 1 activity in oral cancer stem cells. Oral cancer
rs, afterward; the intracellular ALDH activity was examined by
ehyde, a specific inhibitor of ALDH1 enzyme, was used as a
sitive cells. The experiments were repeated three times and
viation. * p< 0.05 versus control.
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OCSC have increased resistance to radiation treatment,
which is commonly used for OSCC patients.22 We therefore
evaluated the effect of luteolin on the radio-sensitivity in
OCSC. During MTT assay, OCSC displayed a radioresistant
phenotype, and the combined treatment of luteolin
enhanced the efficacy of radiation in OCSC (Fig. 4A). To
determine whether combined treatment with luteolin and
radiation would affect the malignancy of enriched OCSC
in vitro, we analyzed the anchorage-independent growth
potential and migration ability of OCSC combined treated
with luteolin and radiation treatment. Moreover, OCSC
treated with the combination luteolin and radiation treat-
ment showed a synergistic effect in promoting elimination
of invasion (Fig. 4B) and colony-forming potentials (Fig. 4C)
of OCSC.
Inhibition of IL-6/Stat3 signaling in OCSC by luteolin
It was found that IL-6/Stat3 signaling is involved in main-
taining CSC properties including OSCC.23 To investigate
further the mechanistic effect interfered by luteolin
treatment to reduce the CSC properties, we examined the
IL-6 secretion and STAT3/p-STAT3 expression of luteolin-
treated OCSC. Enzyme-linked immunosorbent assay anal-
ysis showed that luteolin treatment decreased IL-6Figure 4 Restored radiosensitivity of oral cancer stem cells (OCS
irradiation, the surviving cell fractions of the control or luteolin-tre
forming ability in OCSC were examined after treatment with either
control; ** p< 0.05 luteolinþ IR versus luteolin alone; *** p< 0.001secretion in OCSC by (Fig. 5A). Immunoblot analyses
showed that the level of phospho-STAT3 protein was
diminished in OCSC treated with luteolin (Fig. 5B). To
elucidate further the involvement of IL-6 the anti-CSC ef-
fects of luteolin, luteolin-associated cancer stemness
repression experiments with the treatment of IL6 in OCSC
were performed. The anti-CSC effects, including self-
renewal capability (Fig. 5C) and invasiveness (Fig. 5D), of
OCSC were rescued by IL-6 treatment. These data suggest
that luteolin-treatment impairs CSC properties through
inactivating the IL-6/STAT3 signaling.
Discussion
Head and neck squamous cell carcinoma, including OSCC, is
one of the most prevalent neoplasms worldwide.24 The poor
survival rate of OSCC could be attributable to either the
late diagnosis of the disease or the potential resistance of
OSCC cells to clinical therapeutic treatments.24 Recent
findings from our group have confirmed that OCSC probably
impart resistance to conventional treatment modalities and
promote tumorigenesis in OSCC.25 Therefore, approaches
that target CSCs for OSCC treatments may provide new way
of clinical practices. In this study, we demonstrated that
luteolin treatment reduced the proliferation and self-
renewal ability in enriched OCSC (Fig. 1). We demon-
strated that luteolin treatment reduced CSC markers suchC) by luteolin treatment. After exposure to different doses of
ated OCSC were evaluated. (B) Invasion ability and (C) colony-
luteolin or radiationtherapy or both. * p< 0.05 luteolin versus
. IR Z infrared radiation.
Figure 5 Inhibition of interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling of oral cancer stem
cells (OCSC) by luteolin treatment. (A) IL-6 secretion level in luteolin-treated OCSC by enzyme-linked immunosorbent assay
analysis; (B) cell extract proteins of luteolin-treated OCSC were collected and analyzed by immunoblotting against anti-p-STAT3,
anti-STAT3, or antiglyceraldehyde 3-phosphate dehydrogenase antibodies as indicated. The immunoactive signal of glyceraldehyde
3-phosphate dehydrogenase protein of different crude cell extracts was referred as loading control; (C) self-renewal; and (D)
invasion ability in OCSC were analyzed after treatment with either luteolin or luteolin combined with IL-6. * p< 0.05 luteolin versus
control; ** p< 0.05 luteolinþ IL-6 versus luteolin alone.
Luteolin enhances radio-sensitivity in OSCC 1037as ALDHþ and CD44þ cells (Figs. 2 and 3). Luteolin effec-
tively restored the synergistic radiosensitivity to irradiation
in OCSC (Fig. 4). To our knowledge, this is the first report
inhibiting the cancer stemness and radioresistance prop-
erties of OCSC by luteolin.
Mechanistically, IL-6/STAT3 signaling is constitutively
activated in various types of cancers including prostate
cancer, breast cancer, leukemia, multiple myeloma, brain
tumors, and OSCC.26,27 Persistent oncogenic STAT3 activa-
tion is associated with poor prognosis of OSCC patients and
promotes malignant progression.28,29 In addition, IL-6/
STAT3 is an important axis for maintaining cancer stem-
like properties and tumorigenesis processes in several ma-
lignant carcinomas, including OSCC.30e32 Korkaya et al33
showed that the IL-6 pathway is responsible for the resis-
tance to trastuzumab and cancer stem cells maintenance in
breast cancer. The clinical treatment of stage 1 and 2 OSCC
includes surgical resection or radiotherapy. For patients
with advanced and metastatic OSCC, both radiation and/or
chemotherapy are the major therapeutic measures. Radi-
oresistance is the major cause of recurrence and metastasis
as well as lethality in OSCC patients. Our previous studies
have demonstrated that OCSC are more resistant to radia-
tion therapy.22 Notably, reports have shown that inhibition
of STAT3 can significantly promote radiosensitivity and
further suppress tumorigenicity.34 Our present findingssuggest that luteolin treatment decreases cancer stemness
and malignancy through inhibition of IL-6 secretion and p-
STAT3 activation (Fig. 5). These findings support the idea of
using the IL-6/STAT3 axis as potential signaling for anti-CSC
therapy, and the inhibition of IL-6/STAT3 signaling by
luteolin treatment may be an important therapy when
combined with radiotherapy.
Taken together, our data indicate that luteolin can
inhibit oncogenicity and radioresistant properties of OCSC
through targeting IL-6/STAT3 signaling. These findings pro-
vide a strong rationale for the potential use of luteolin as a
radiosensitizer and anti-CSCs agent.
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